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Contr ncCHF cCHF ncCHF cCHF cCHF
vs Con vs Con vs ncCHF
n =21 n =29 n = 19 (P=) (P=) (P=)
sTNF.RI. nalml 0,6 + 0.061.1 + 0.18 1.7+ 0.170.03 0.02 <0.0001. . .. .... ....
sCD14, @/ml 2.7 + 0.11 3.2+ 0.16 3.8+23 0.07 0.0001 0.009
Leptin,n@ml 4.8 + 0.7 9.4+ 1.1 5.3+ 0.7 0.0005 NS 0,002
BodyFaffheight,@cm 106+10 123+9 60+ 5 0.20 0.03 0,0006
BodyLaatiheight, #cm 327 i 6 326 & 7 270 + 5 NS <0.0001 <0.0001
mean + SEM, nc = non-cechactlc,NS = p >0.20
overall, Ieptin correlated with fat tissue content (r = 0.70), ineulin (r =
0.72), weight and BMI (all p c 0.0001), but no! with cytokinee. Fat tiseue
content ve insulin (r= 0.49, p c 0.0001), vs sTNF-RI (r= –0.37), ve NA (r =
-0.34, troth p < 0.006). Lean tissue content sTNF-RI (r= –0.41), vs NA (r
= -0.39), veTNF-u (r = –0.36, all p < 0.003).
Corrclusiom Cardiac cachexia is not characteriead by Ieptin overproduc-
tion (anorexia via thie pathway is unlikely), but ie rather a Cataboliccondition
related to immune and neurohormonal activation.
m1083121 DiagnosticsndPrognosticValuaof SolublaInterleukin2 ReceptorintheSerumof Patients
withIdiopathicor lschemicDilated
Cardiomyopathy
G. Klappacher, D. Haab, M. Mehrabi, K. Plesch, R. Pacher, W. Kukutschki,
H.D. Glogar. University of Vienna, Vienna, Austria
We and others have recently reportad that circulating levels of soluble ln-
terleukin 2 receptor (sIL2R) are increased in patients with idiopathic dilated
cardiomyopathy suggesting cellular autoimmune activation. In the present
etudy we looked at the specificity, the diagnostic and predictive value of
serum sIL2R. In agreement with previous observations, 34 patients with
idiopathic dilated cardiomyopathy had higher Ievele of elL2R than healthy
controls (756 + 76.6 vs. 461.2 + 35.9 U/mL, p -=0.01). All 5 deaths during
the follow-up period of 690 * 57 days occurred among the patients with
serum elL2R >750 U/mL (log rank test, p e 0.00001), who also were more
likely to receive a heart transplant (odds ratio 6.5 (1.3-357.9)). Moreover,
patienta in NYHA claeeee Ill and IV, with eerum eodium <136 mmol/L and
furoeemide doeage z 100 mgfday had significantly higher serum concentra-
tion of sI12R than patiente in NYHA claesee I and 11,with eerum sodium ?
136 mmoVL and furosemide dosage <100 m~day, respectively. In 24 pe-
tiente with ieehemic cardiomyopathy eerum sIL2R was also increased above
control levels (619.7 + 36.3 U/mL, p c 0.025), but it was not associated
with the clinieel stage. Neither in ischemic nor in idiopathic dilated cardiomy-
opathy serum sIL2R correlated with the counts of CD2-, CD3-, CD4-, CD6-,
CD46R0-, and lL2R-positive cells in croee eecfione of the explantad hearte
of 15 transplant recipients among the total of 66 patients. Conclusion: Serum
sIL2R pradiete death and indicatee progression of dieeeee in patients with
idiopathic dilated cardiomyopathy. However, its increaae is not mnfinad to
the idiopathic form and does not necessarily reflect immune activation in the
myoeerdium.
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m1084135 LeftVentricularHypertrophylaAssociatedwithAbnormalAdenoalneAl-ReceptorSignalingand
Adenostne-inducedProteinKinaaeC Activation
S. Perlinl, E.P. Khoury, E.S. Chung, F. Bartl, R.A. Fenton, J.G. Dobeon,Jr.,
T.E. Meyer. Urriversityof Massachusetts Medical Cantec Worcester MA,
USA
To aesees the effect of prolonged adenosine (Ado) infueion on adrenergic
reeponsivensse (AR) in left ventricular hypartrophy (LVH), rat hearta were
isolated and perfused at 10 wke after aortic banding (B, heart weight index
increased by 50Yo) or sham surgery (S). AR (+dP/dk~) to 10-8 M isopro-
terenol was determined before (C) and at 60 min of 3.3 x 10-5M of Ado or
NaCl infueion, andafter 15, 30and45min of Ado waeh-out(tVO). Responses
were expressad as a % of C. This protocol was repeated with Ado and a)
a eeleetive AI antagonist, 6-cyclopentyl-1,3-diproPYlxanthine(lO-eM, CPX),
b) a protein kinase C (PKC) inhibitor, chelerythrine (2 x 10-6M, Chel) ore) a
PKC activator, phorbcd12-myristate 13-acetate (10-9M, PMA).
% dP/dt of C ‘A dP/dt of C followinaAdo WP
-w
60 mifl infusion: 15 rein: 30 mln: 45 mln:
S-NaCl (n = 7) 95+ 5 91 & 6 96% 6 96& 4
S-Ado (n= 10) 31 *6* 51 *4* 61 k 6“ 74• 9*
S-Ado +Chel (n = 13) 34* 3* S4• 5t 96 h 7t 99* 7t
S-NaCl (n =7) 97 i 4 96& 4 96& 4 99* 3
B-Ado (n =24) 50* 5*t 65+ 5*t 91 i 7t 99& 8t
B-Ado+ CPX (n =7) 56& 7“f 91 * 9t 97* 12t 101 * 14t
B-Ado + Chel (n =9) 38& 4*$ 99* fl 95* 3t 99 i 7f
B-Ado+ PMA (n = 4) 56& 7*f 60+ 7*# 67& 7** 72 & 10*#
Means k SEM; *p <0.05 vs NaCl; tp <0.05 vs S-Ado;#p <0.05 vs B-Ado.
Interstitial Ado levels returned to baseline within 5 min of WO. Ado expo-
sure in S caused a marked adrenergic depreeeion (AD) at 60 min of infusion.
AD persisted up to 45 min after Ado WO. This lingering AD was preventad
by PKC inhibition. In LVH the initial AD was Ieea marked and the rscovety
was much faeter. An Al-antagonist or a PKC inhibitor did not affeef this re-
sponse, whereas pronounced lingering AD wee elicited after PMA-induced
PKC activation. Conclusion: In LVH Al-receptor signaling and Ado-induced
PKC activation are abnormal.
I 1084-I36I AbnormalCalciumHandlingprOPerty
ProgressesfromtheAdjacentto Remote
Non-lrtfarctedMyocardiumafterMyocardial
Infarction
Y. Takemoto, M. Yoshiyama, K. Takeuchi, A. Hanateni, N. Shimizu,
H. Yamagishi, 1.Toda, J. Yoshikawa. First Department of Internal Medicine,
Osaka City IJniversifyMedical School, Osaka, Japan
Cardiac dysfunction after myocarclialinfarefion develops with time. However,
the cauae is still unknown. We have a hypothesis that abnormal calcium
handling pmpetty progresses fmm the adjacent non-infarcted left ventricle
(adjacent LV) to remote non-infarcted LV after myocerdial infarction (Ml) and
induces cardiac dysfunction. The purpose of this study was to examine the
time course of cardiac function by schoeerdiograms and gene expression in
the adjacent and remote LV and right ventricles (RV) of rate’at 1, 3 and 6
months after Ml in rate. (Each group n =6)
1 month 3 months 6 months
LVEDP ~mmHa} 22* 2** 25& 3** 26+3**
LVEDV ~m!Jkg)-’ 1.52 +0.14’”
LVEF (“A) 35+3**
LVwt (@kg) 2.16+ 0.19’
RVwt (@kg) 0.74* 0.10”
E velocity(cnVs) 84& 2
A velocity(cWS) 22+ 3
EIA 4.2 + 0.5”
E Decele (rdsz) 16.1 &2.t*
1,70+ 0.13**
30*4**
2.29 + 0.17””
0.86 *0.11””
95 *3*
16 *3*
9.5* 2.2**
22.3 h 2.6**
1.96+ 0.16**
26*4”*
2.42 & 0.20**
0,92 + 0.14””
101 *3*
12 +3*
12.3+2.1””
30.4* 1.7**
SR Ca (foid)
AdjacentLV 1.0+ 0.2 0.7 l 0.1” 0.3+0.0””
Remote LV 1.0 l 0.1 1.* 0.1 0.7 l 0.0*
Rv 1.0 i 0.2 0,7+ 0.2” 0.6 + O.l”+,.
Na-Ca (told)
AdjacentLV 1.6 + 0.2** 0.9 * 0.1 0.5+ 0.1””
Remote LV 1.9 * 0.2”’ 1.8 +0.2”” 1.0 +0.1
RV 2.0 + 0.2”” 1.6 & 0.2”” 1.1 +0.2
*P <0,05, **P < 0,01: comparedto sham operated rats
Gene expressions of fetal contractile proteins (~-myosin heavy chain,
a-ekeletal aetin, ANP) and collagen 1,Ill were highest at 1 M after Ml. In
conclusion, cardiac dysfunction, decreased gene expression of SR-Ca and
Na-Ca advanced from the adjacent to remote LV with time.
11084-137I EffecteofNitricOXideSYntha*lnhibitiononthe
VenousTonein RatawithHeatiFailure
T. Hirai, H. Asanoi, T.1.Musch, H. Inoue. ToyarrsaMedical& Pharmaceutical
University Toyama,Japan, Kanaas State Universi~ Manhattan, KS, USA
Recent studies have demonstrated that nitric oxide (NO) mcdulatee bseeline
venous tone. To determine the functional mle of NO in the regulation of va-
noustone in normal rats and rats with chronic heart failure (CHF), we etudied
the effect of NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of NO
synthesis, in chloralose-anesthetized Wister rats with CHF due to myoeerdlal
infarction (Ml; n = 11) (Ml eize; 41 + 5% of the left ventricular endocerdial
circumference) and sham operatad rats (SHAM; n = 10). Mean circulatory
filling preesure (MCFP), the equilibrated eystemic pressure occurring when
the circulation is arrestad by transient inflation of a balloon in the right atrium,
was meaeured before and after L-NAME (1, 3, 10, 20 mg/kg, iv.) adminis-
tration. MCFP was used as an index of total venoua capacitance. Baseline
